Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
1997-09-19
2004-02-17
Goldberg, Jerome D. (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
Reexamination Certificate
active
06693127
ABSTRACT:
BACKGROUND OF THE INVENTION
Cancer is a leading cause of death in the United States and affects people worldwide. Surgery, radiation and chemotherapy are the most widely used therapeutic modalities. Chemotherapy agents create conditions within the cell that limit cell growth and replication. DNA synthesis may be inhibited by preventing purine biosynthesis, pyrimidine biosynthesis, the conversion of ribonucleotides to deoxyribonucleotides, antimetabolites, intercalation, or cross-links. RNA synthesis, for example, may be inhibited by antimetabolites. Protein synthesis may be inhibited, for example, by agents that deaminate asparagine. Additionally, agents that inhibit the function of microtubules can be used as chemotherapy agents.
Chemotherapy agents typically affect both neoplastic and rapidly proliferating cells of normal tissue such as bone marrow, hair follicles and intestinal epithelium. Anorexia, nausea, vomiting, diarrhea, suppression of bone marrow function and hair loss are some of the negative effects commonly associated with chemotherapy. Development of a chemotherapy agent that is an effective antitumor agent with minimal toxicity would be advantageous.
SUMMARY OF THE INVENTION
It has been discovered that arglabin and various derivatives of arglabin can function as effective chemotherapeutic agents, with fewer side-effects than typically follow from use of other chemotherapeutic agents.
In one aspect, the invention features a pharmaceutical composition in unit dosage form suitable for the treatment of a human cancer. The composition consists essentially of about 40 mg to about 480 mg of arglabin or a derivative thereof. The unit dosage of the composition may be, for example, from about 175 mg to about 315 mg or from about 240 mg to about 280 mg. The composition is useful for the treatment of a wide variety of cancers, including, for example, breast, colon, rectal, stomach, pancreatic, lung, liver, ovarian, pancreatic and esophageal cancer, leukemia, and lymphoma. The method is particularly useful for the treatment of lung, liver, and ovarian cancer.
Dimethylaminoarglabin or a pharmaceutically acceptable salt thereof is a particularly useful arglabin derivative that may be used in the pharmaceutical composition. Dimethylaminoarglabin or a pharmaceutically acceptable salt thereof may be lyophilized.
The invention also features an article of manufacture including packaging material and a pharmaceutical agent contained within the packaging material that is therapeutically effective for suppressing tumor growth in a human. The packaging material includes a label that indicates that the pharmaceutical agent can be used for suppressing tumor growth in a human. The pharmaceutical agent includes arglabin or a derivative thereof. A derivative of arglabin that is particularly useful is dimethylaminoarglabin or a pharmaceutically acceptable salt thereof.
Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, suitable methods and materials are described below. All publications, patent applications, patents, and other references mentioned herein are incorporated by reference in their entirety. In case of conflict, the present specification, including definitions, will control. In addition, the materials, methods, and examples are illustrative only and not intended to be limiting.
Other features and advantages of the invention will be apparent from the following detailed description, and from the claims.
REFERENCES:
patent: 5663196 (1997-09-01), Sari et al.
patent: 1185 (1993-12-01), None
patent: 1186 (1993-12-01), None
patent: 1187 (1993-12-01), None
patent: 1188 (1993-12-01), None
patent: 1189 (1993-12-01), None
patent: 1190 (1993-12-01), None
patent: 1192 (1993-12-01), None
patent: 1193 (1993-12-01), None
patent: 909 (1994-06-01), None
patent: 153K (1997-05-01), None
patent: 1746674 (1992-03-01), None
S. M. Adekenov, K.M. Turdybekov, K.A. Aituganov, S. V. Lindeman, Yu T. Struchkov, and S. N. Shaltakov, “1&bgr;, 10&agr;-Dihydroxyarglabin—A New Sesquiterpene Lactone from Artemisia glabella,” Chemistry of Natural Compounds, vol. 29, No. 6, 1993, pp. 735-739.
“The Merck Index,” Merck & Co., 1983, pp. 329, 394, 408, 599, 1427 and 1428.
Blanco et al., “A novel activity for a group of sesquiterpene lactones: inhibition of aromatase,” FEBS Letters vol. 409, No. 3, (1997) pp. 396-400.
Giordano et al., “The Gastric Cytoprotective Effect of Several Sesquiterpene Lactones,” Journal of Natural Products, vol. 53, No. 4. pp. 803-809, Jul.-Aug. 1990.
Guardia et al., “Mucus Synthesis and Sulfhydryl Groups in cytoprotection mediated by Dehydroleucodine, A Sesquiterpene Lactone,” Journal of Natural Products, vol. 57, No. 4. pp. 507-509, Apr. 1994.
Barbacid, M., Ann. Rev. Biochem., 56:779-827 (1987).
Gibbs et al., Proc. Natl. Acad. Sci. USA, vol. 81, pp. 5704-5708 (Sep. 1984).
Jung et al., Mol. Cell. Biol., vol. 14, No. 6, pp. 3707-3718 (Jun. 1994).
Marom et al., J. Biol. Chem., vol. 270, No. 38, pp. 22263-22270 (1995).
Prendergast et al., Mol. Cell. Biol., vol. 14, No. 6, pp. 4193-4202 (Jun. 1994).
Shears et al., Biochem. J., vol. 219, pp. 375-382 (1984).
Vogt et al., J. Biol. Chem., vol. 270, No. 2, pp. 660-664 (1995).
Adekenov et al., Fitoterapia, vol. LXVI, No. 2, pp. 142-146 (1995).
Bottex-Gauthier et al., Biotechnology Therapeutics, 4(1&2), pp. 77-98 (1993).
Epstein et al., Proc. Natl. Acad. Sci. USA, vol. 88, pp. 9668-9670 (Nov. 1991).
Adekenov et al., Institute of Chemical Metallurgy, Academy of Sciences of the Kazakh SSR, Karaganda—Translated from Khimiya Prirodnykh Soedinenii, No. 5, pp. 655-656, Sep.-Oct. 1982 (1 page).
Goldberg Jerome D.
Jenkens & Gilchrist
Matney, Jr. W. Jackson
Paracure, Inc.
LandOfFree
Pharmaceutical compositions of arglabin and arglabin... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pharmaceutical compositions of arglabin and arglabin..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pharmaceutical compositions of arglabin and arglabin... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3353519